168 related articles for article (PubMed ID: 10897808)
1. Importance of oral antimetabolite "maintenance" therapy in childhood lymphoblastic leukemia.
Lilleyman JS
Pediatr Hematol Oncol; 1996; 13(5):vii-x. PubMed ID: 10897808
[No Abstract] [Full Text] [Related]
2. Pharmacokinetics and pharmacodynamics of oral methotrexate and mercaptopurine in children with lower risk acute lymphoblastic leukemia: a joint children's cancer group and pediatric oncology branch study.
Balis FM; Holcenberg JS; Poplack DG; Ge J; Sather HN; Murphy RF; Ames MM; Waskerwitz MJ; Tubergen DG; Zimm S; Gilchrist GS; Bleyer WA
Blood; 1998 Nov; 92(10):3569-77. PubMed ID: 9808549
[TBL] [Abstract][Full Text] [Related]
3. Myelotoxicity, pharmacokinetics, and relapse rate with methotrexate/6-mercaptopurine maintenance therapy of childhood acute lymphoblastic leukemia.
Schmiegelow K; Ifversen M
Pediatr Hematol Oncol; 1996; 13(5):433-41. PubMed ID: 10897815
[TBL] [Abstract][Full Text] [Related]
4. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia.
Relling MV; Hancock ML; Boyett JM; Pui CH; Evans WE
Blood; 1999 May; 93(9):2817-23. PubMed ID: 10216075
[TBL] [Abstract][Full Text] [Related]
5. Compliance with oral chemotherapy in childhood lymphoblastic leukaemia.
Davies HA; Lilleyman JS
Cancer Treat Rev; 1995 Mar; 21(2):93-103. PubMed ID: 7758006
[No Abstract] [Full Text] [Related]
6. 6-mercaptopurine dosage and pharmacokinetics influence the degree of bone marrow toxicity following high-dose methotrexate in children with acute lymphoblastic leukemia.
Schmiegelow K; Bretton-Meyer U
Leukemia; 2001 Jan; 15(1):74-9. PubMed ID: 11243403
[TBL] [Abstract][Full Text] [Related]
7. Optimizing antimetabolite-based chemotherapy for the treatment of childhood acute lymphoblastic leukaemia.
Estlin EJ; Lowis SP; Hall AG
Br J Haematol; 2000 Jul; 110(1):29-40. PubMed ID: 10930977
[No Abstract] [Full Text] [Related]
8. Physiologically based pharmacokinetic modelling of methotrexate and 6-mercaptopurine in adults and children. Part 2: 6-mercaptopurine and its interaction with methotrexate.
Ogungbenro K; Aarons L;
J Pharmacokinet Pharmacodyn; 2014 Apr; 41(2):173-85. PubMed ID: 24651962
[TBL] [Abstract][Full Text] [Related]
9. Effects on transmethylation by high-dose 6-mercaptopurine and methotrexate infusions during consolidation treatment of acute lymphoblastic leukemia.
Keuzenkamp-Jansen CW; De Abreu RA; Blom HJ; Bökkerink JP; Trijbels JM
Biochem Pharmacol; 1996 May; 51(9):1165-71. PubMed ID: 8645339
[TBL] [Abstract][Full Text] [Related]
10. Defining the optimal dosage of methotrexate for childhood acute lymphoblastic leukemia. New insights from the lab and clinic.
Evans WE; Pui CH; Relling MV
Adv Exp Med Biol; 1999; 457():537-41. PubMed ID: 10500831
[No Abstract] [Full Text] [Related]
11. Six months of maintenance chemotherapy after intensified treatment for acute lymphoblastic leukemia of childhood.
Toyoda Y; Manabe A; Tsuchida M; Hanada R; Ikuta K; Okimoto Y; Ohara A; Ohkawa Y; Mori T; Ishimoto K; Sato T; Kaneko T; Maeda M; Koike Ki; Shitara T; Hoshi Y; Hosoya R; Tsunematsu Y; Bessho F; Nakazawa S; Saito T
J Clin Oncol; 2000 Apr; 18(7):1508-16. PubMed ID: 10735899
[TBL] [Abstract][Full Text] [Related]
12. Oral methotrexate/6-mercaptopurine may be superior to a multidrug LSA2L2 Maintenance therapy for higher risk childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study.
Schmiegelow K; Heyman M; Kristinsson J; Mogensen UB; Rosthøj S; Vettenranta K; Wesenberg F; Saarinen-Pihkala U;
J Pediatr Hematol Oncol; 2009 Jun; 31(6):385-92. PubMed ID: 19648786
[TBL] [Abstract][Full Text] [Related]
13. The interaction of 6-mercaptopurine (6-MP) and methotrexate (MTX).
Giverhaug T; Loennechen T; Aarbakke J
Gen Pharmacol; 1999 Oct; 33(4):341-6. PubMed ID: 10523073
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of tablet and liquid formulations of oral 6-mercaptopurine in children with acute lymphoblastic leukemia.
Larsen RH; Hjalgrim LL; Grell K; Kristensen K; Pedersen LG; Brünner ED; Als-Nielsen B; Schmiegelow K; Nersting J
Cancer Chemother Pharmacol; 2020 Jul; 86(1):25-32. PubMed ID: 32519032
[TBL] [Abstract][Full Text] [Related]
15. Effect of methotrexate polyglutamates on thioguanine nucleotide concentrations during continuation therapy of acute lymphoblastic leukemia with mercaptopurine.
Dervieux T; Hancock M; Evans W; Pui CH; Relling MV
Leukemia; 2002 Feb; 16(2):209-12. PubMed ID: 11840287
[TBL] [Abstract][Full Text] [Related]
16. Serendipity-methotrexate and 6-mercaptopurine for continuation therapy for patients with acute lymphoblastic leukemia: the leukemic stem cell and beyond?
Kamen BA
J Pediatr Hematol Oncol; 2009 Jun; 31(6):383-4. PubMed ID: 19648785
[No Abstract] [Full Text] [Related]
17. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus.
Relling MV; Hancock ML; Rivera GK; Sandlund JT; Ribeiro RC; Krynetski EY; Pui CH; Evans WE
J Natl Cancer Inst; 1999 Dec; 91(23):2001-8. PubMed ID: 10580024
[TBL] [Abstract][Full Text] [Related]
18. Repetitive low dose oral methotrexate and intravenous mercaptopurine treatment for patients with lower risk B-lineage acute lymphoblastic leukemia. A Pediatric Oncology Group pilot study.
Mahoney DH; Camitta BM; Leventhal BG; Shuster JJ; Civin CJ; Ganick DJ; Lauer SJ; Steuber CP; Kamen BA
Cancer; 1995 May; 75(10):2623-31. PubMed ID: 7736409
[TBL] [Abstract][Full Text] [Related]
19. A mathematical model of white blood cell dynamics during maintenance therapy of childhood acute lymphoblastic leukemia.
Le TTT; Jost F; Raupach T; Zierk J; Rauh M; Suttorp M; Stanulla M; Metzler M; Sager S
Math Med Biol; 2019 Dec; 36(4):471-488. PubMed ID: 30357334
[TBL] [Abstract][Full Text] [Related]
20. Intermediate-dose methotrexate versus cranial irradiation in childhood acute lymphoblastic leukemia: a ten-year follow-up.
Freeman AI; Boyett JM; Glicksman AS; Brecher ML; Leventhal BG; Sinks LF; Holland JF
Med Pediatr Oncol; 1997 Feb; 28(2):98-107. PubMed ID: 8986145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]